196 related articles for article (PubMed ID: 10699766)
1. Characterization of acyclovir susceptibility and genetic stability of varicella-zoster viruses isolated during acyclovir therapy.
Ida M; Kageyama S; Sato H; Kamiyama T; Toyomoto T; Ozaki T; Kajita Y; Morohashi M; Shiraki K
J Dermatol Sci; 2000 May; 23(1):63-72. PubMed ID: 10699766
[TBL] [Abstract][Full Text] [Related]
2. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
Mercier-Darty M; Boutolleau D; Lepeule R; Rodriguez C; Burrel S
Antiviral Res; 2018 Mar; 151():20-23. PubMed ID: 29337163
[TBL] [Abstract][Full Text] [Related]
3. Resistance testing of clinical varicella-zoster virus strains.
Sauerbrei A; Taut J; Zell R; Wutzler P
Antiviral Res; 2011 Jun; 90(3):242-7. PubMed ID: 21539861
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS.
Talarico CL; Phelps WC; Biron KK
J Virol; 1993 Feb; 67(2):1024-33. PubMed ID: 8380452
[TBL] [Abstract][Full Text] [Related]
5. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
6. Acyclovir-resistant varicella-zoster virus: phenotypic and genetic characterization.
Fillet AM; Dumont B; Caumes E; Visse B; Agut H; Bricaire F; Huraux JM
J Med Virol; 1998 Jul; 55(3):250-4. PubMed ID: 9624615
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir.
Morfin F; Thouvenot D; De Turenne-Tessier M; Lina B; Aymard M; Ooka T
Antimicrob Agents Chemother; 1999 Oct; 43(10):2412-6. PubMed ID: 10508017
[TBL] [Abstract][Full Text] [Related]
8. Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants.
Ida M; Kageyama S; Sato H; Kamiyama T; Yamamura J; Kurokawa M; Morohashi M; Shiraki K
Antiviral Res; 1999 Jan; 40(3):155-66. PubMed ID: 10027650
[TBL] [Abstract][Full Text] [Related]
9. Acyclovir treatment prevents varicella-zoster virus replication in PBMC during viremia.
Wolff MH; Schünemann S
New Microbiol; 1999 Oct; 22(4):309-14. PubMed ID: 10555200
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet.
Bleymehl K; Cinatl J; Schmidt-Chanasit J
Med Microbiol Immunol; 2011 Aug; 200(3):193-202. PubMed ID: 21373931
[TBL] [Abstract][Full Text] [Related]
11. Differences in the Likelihood of Acyclovir Resistance-Associated Mutations in the Thymidine Kinase Genes of Herpes Simplex Virus 1 and Varicella-Zoster Virus.
Fujii H; Harada S; Yoshikawa T; Yamada S; Omura N; Shibamura M; Inagaki T; Kato H; Fukushi S; Saijo M
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858222
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS.
Boivin G; Edelman CK; Pedneault L; Talarico CL; Biron KK; Balfour HH
J Infect Dis; 1994 Jul; 170(1):68-75. PubMed ID: 8014522
[TBL] [Abstract][Full Text] [Related]
13. Acyclovir-resistant varicella-zoster virus keratitis in an immunocompetent patient.
Gueudry J; Boutolleau D; Gueudin M; Burrel S; Miri A; Bodaghi B; Muraine M
J Clin Virol; 2013 Sep; 58(1):318-20. PubMed ID: 23756055
[TBL] [Abstract][Full Text] [Related]
14. Compartmentalization of acyclovir-resistant varicella zoster virus: implications for sampling in molecular diagnostics.
Brink AA; van Gelder M; Wolffs PF; Bruggeman CA; van Loo IH
Clin Infect Dis; 2011 Apr; 52(8):982-7. PubMed ID: 21460310
[TBL] [Abstract][Full Text] [Related]
15. A rapid phenotypic assay for detection of acyclovir-resistant varicella-zoster virus with mutations in the thymidine kinase open reading frame.
Sahli R; Andrei G; Estrade C; Snoeck R; Meylan PR
Antimicrob Agents Chemother; 2000 Apr; 44(4):873-8. PubMed ID: 10722484
[TBL] [Abstract][Full Text] [Related]
16. Advances in the treatment of varicella-zoster virus infections.
Andrei G; Snoeck R
Adv Pharmacol; 2013; 67():107-68. PubMed ID: 23886000
[TBL] [Abstract][Full Text] [Related]
17. [Antiviral drug therapy of infections caused by Herpes simplex and Varicella Zoster viruses].
Vogt M; Huss R; Wunderli W
Schweiz Med Wochenschr; 1992 Apr; 122(16):569-75. PubMed ID: 1579862
[TBL] [Abstract][Full Text] [Related]
18. [Contribution of the laboratory in case of resistance to acyclovir of herpes simplex and varicella zoster virus].
Morfin F; Frobert E; Thouvenot D
Ann Biol Clin (Paris); 2003; 61(1):33-40. PubMed ID: 12604384
[TBL] [Abstract][Full Text] [Related]
19. Isolation of drug resistant mutants of varicella-zoster virus: cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine.
Shiraki K; Ogino T; Yamanishi K; Takahashi M
Biken J; 1983 Mar; 26(1):17-23. PubMed ID: 6312958
[TBL] [Abstract][Full Text] [Related]
20. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.
Andrei G; Sienaert R; McGuigan C; De Clercq E; Balzarini J; Snoeck R
Antimicrob Agents Chemother; 2005 Mar; 49(3):1081-6. PubMed ID: 15728906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
